Skip to main content
letter
. 2015 May;100(5):e207–e210. doi: 10.3324/haematol.2014.118182

Table 2.

Best confirmed response rates and time-to-event outcomes with SC and IV bortezomib (± dexamethasone) according to renal subgroup (CrCl 20–50 or >50 mL/min), in response-evaluable patients (those with measurable, secretory multiple myeloma who received ≥1 dose of bortezomib; response rates and time to response) or the intent-to-treat population (other outcomes).

graphic file with name 100e207.tab2.jpg